MedPath

Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation

Phase 1
Completed
Conditions
Pulmonary Disease
Pulmonary Hypertension
Interventions
Radiation: 99mTC-PulmoBind
Registration Number
NCT01539889
Lead Sponsor
Montreal Heart Institute
Brief Summary

Pulmonary hypertension (PH) can be the result of various clinical conditions. It may be idiopathic or associated with various cardiovascular and lung disorders. Currently there is no test that can non-invasively detect abnormalities of the pulmonary circulation. There is a growing need for a non-invasive method to detect PH. There currently exists only ne agent approved in Canada for clinical imaging of the pulmonary circulation, 99mTc-labeled macroaggregates. This agent is exclusively used for the diagnosis of physical defects of the circulation due to pulmonary embolus. This agent is larger than small pulmonary vessels, limiting its sensitivity to detect small vascular defects, as well as potential infectious risks since albumin macroaggregates are derived from human albumin. There is need then for new lung tracers that could provide a greater safety profile while enabling functional as well as anatomical imaging of the pulmonary circulation. DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Hence the development of this novel AM derivative, PulmoBind, for molecular imaging of the pulmonary circulation. PulmoBind is labeled with 99mTc, the most commonly used imaging isotope in nuclear medicine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • male or female greater than 18 years of age. Female subjects must be post-menopausal (defined as two years after menstrual cycle)
  • within normal range for the following: BP systolic 100-140 mmHg and diastolic 50-90 mmHg;
  • HR 60-100 beats per minute;
  • oral temperature less than 37.6 degrees Centigrade;
  • respiratory rate 12-20 breaths per minute;
  • normal lung function tests;
  • normal echocardiogram including estimation of pulmonary artery systolic pressure;
  • normal chest x-ray; Normal electrocardiogram
Exclusion Criteria
  • any known chronic or acute medical condition with or without the need for chronic pharmacologic therapy or any condition that may interfere with normal biodistribution of DFH-12. Includes but not limited to:

    • lung parenchymal or lung vascular diseases such as chronic obstructive pulmonary disease,
    • bronchitis,
    • lung cancer,
    • pleural effusion,
    • emphysema,
    • asthma,
    • pulmonary fibrosis,
    • occupational lung disease,
    • pulmonary hypertension (primary or secondary),
    • systemic hypertension,
    • diabetes,
    • cancer,
    • kidney disease,
    • liver disease,
    • heart failure or previous myocardial infarction,
    • coronary artery disease,
    • peripheral vascular disease or inflammatory disease;
  • subjects requiring chronic administration of any substance for a medical condition, active smoking or history of smoking for more than one year in the past 10 years, known self-reported alcoholism (active or abstinent);

  • unable to tolerate study procedures ex.(venipuncture, movement restrictions during imaging);

  • previous nuclear study since one week (to avoid cross-contamination)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
DFH-12 PulmoBind99mTC-PulmoBindDFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
Primary Outcome Measures
NameTimeMethod
To determine optimal dose of PulmoBind to be administered for lung imaging in humans48 hours

To determine the optimal dose of Pulmobind by evaluating the safety and efficacy in three groups of subjects with 3 different doses of study drug; 5mCi, 10mCi, and 15 mCi.For safety evaluation we will provide pharmacokinetic and biodistribution data following injections of the 3 doses mentioned. Vital signs, hematology and biochemistry will also be captured for each of the doses up to 24 and 48 hours after injections of PulmoBind. Furthermore local and systemic reactions 24 hours and 48 hours after injections of PulmoBind will also be captured.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Montreal Heart Institute

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath